Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: con

12 April 2026 (08:00 - 15:30)

Organised by:

Sign in for access options

About the speaker

Doctor Nikolaos Dagres

Charité - University Medicine Berlin, Berlin (Germany)

5 More presentations in this session

Presentation thumbnail

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: pro

Professor C. Sticherling (Basel, CH)

Presentation thumbnail

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: discussion

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: pro

Doctor J. Karvonen (Helsinki, FI)

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: con

Associate Professor G. Upadhyay (Chicago, US)

Presentation thumbnail

The left bundle branch pacing-shock lead will become standard in implantable cardioverter-defibrillator therapy: discussion

Access the full session

Session thumbnail

Debate on cardiac implantable electronic device therapy

The Event

Event poster

EHRA 2026

12 April - 14 April 2026

You may be interested in

Congress Session

Update on sudden cardiac death – Focus on PROFID EHRA & RESET-CRT

Congress Session

The role of the primary prevention defibrillator after myocardial infarction in the era of modern heart failure therapy: the PROFID project

Congress Presentation

Implantable cardioverter-defibrillator therapy is indicated in all patients with ischaemic cardiomyopathy and severe systolic dysfunction: pro

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources